DK1140165T3 - Fordbedrede adjuvanssammensætninger baseret på saponin og dermed tilhörende metoder - Google Patents

Fordbedrede adjuvanssammensætninger baseret på saponin og dermed tilhörende metoder

Info

Publication number
DK1140165T3
DK1140165T3 DK99968288T DK99968288T DK1140165T3 DK 1140165 T3 DK1140165 T3 DK 1140165T3 DK 99968288 T DK99968288 T DK 99968288T DK 99968288 T DK99968288 T DK 99968288T DK 1140165 T3 DK1140165 T3 DK 1140165T3
Authority
DK
Denmark
Prior art keywords
saponin
compositions based
associated methods
adjuvant compositions
adjuvant
Prior art date
Application number
DK99968288T
Other languages
Danish (da)
English (en)
Inventor
John Walker
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd filed Critical Csl Ltd
Application granted granted Critical
Publication of DK1140165T3 publication Critical patent/DK1140165T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
DK99968288T 1999-01-08 1999-12-24 Fordbedrede adjuvanssammensætninger baseret på saponin og dermed tilhörende metoder DK1140165T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP8073A AUPP807399A0 (en) 1999-01-08 1999-01-08 Improved immunogenic lhrh composition and methods relating thereto
PCT/AU1999/001167 WO2000041720A1 (fr) 1999-01-08 1999-12-24 Compositions adjuvantes ameliorees a base de saponine et procedes en rapport

Publications (1)

Publication Number Publication Date
DK1140165T3 true DK1140165T3 (da) 2009-02-16

Family

ID=3812278

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99968288T DK1140165T3 (da) 1999-01-08 1999-12-24 Fordbedrede adjuvanssammensætninger baseret på saponin og dermed tilhörende metoder

Country Status (15)

Country Link
US (2) US9579379B1 (fr)
EP (2) EP1946773A3 (fr)
JP (2) JP4949555B2 (fr)
AT (1) ATE410183T1 (fr)
AU (2) AUPP807399A0 (fr)
CA (2) CA2359111C (fr)
CY (1) CY1108693T1 (fr)
DE (1) DE69939706D1 (fr)
DK (1) DK1140165T3 (fr)
ES (1) ES2317708T3 (fr)
NZ (1) NZ512011A (fr)
PT (1) PT1140165E (fr)
TW (1) TW533079B (fr)
WO (1) WO2000041720A1 (fr)
ZA (1) ZA200105543B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US7776343B1 (en) 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
GB0008879D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
GB0008877D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
AU2005335104C1 (en) * 2004-07-18 2010-10-28 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
RU2007143992A (ru) * 2005-06-01 2009-07-20 Пфайзер Продактс Инк. (Us) Вакцинные композиции и способы лечения недержания мочи
WO2008110912A1 (fr) * 2007-03-14 2008-09-18 Pfizer Inc. Régulation de fertilité chez des chevaux
EP2865389A1 (fr) 2008-12-09 2015-04-29 Pfizer Vaccines LLC Vaccin peptidique IgE CH3
CA2757620C (fr) 2009-04-30 2016-04-26 Coley Pharmaceutical Group, Inc. Vaccin anti-pneumococcique et ses utilisations
KR20120049900A (ko) 2009-07-30 2012-05-17 화이자 백신스 엘엘씨 항원성 타우 펩타이드 및 이의 용도
CN102612558B (zh) 2009-09-03 2015-02-11 辉瑞疫苗有限责任公司 Pcsk9疫苗
KR20120120185A (ko) 2009-12-22 2012-11-01 셀덱스 쎄라퓨틱스, 인크. 백신 조성물
US8895017B2 (en) 2010-06-07 2014-11-25 Pfizer Inc. HER-2 peptides and vaccines
EP2575868A1 (fr) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Vaccin peptidique ige ch3
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
MX352604B (es) * 2011-05-13 2017-11-30 Zoetis Llc Composiciones inmunogenicas de la glucoproteina g de los virus hendra y nipah.
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
EP2659906A1 (fr) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (fr) 2012-05-01 2013-11-06 Affiris AG Compositions
CN109675025A (zh) 2013-09-19 2019-04-26 硕腾服务有限责任公司 油基佐剂
MX2016007870A (es) 2013-12-16 2016-10-07 Zoetis Services Llc Composiciones inmunogenas de glucoproteina g de los virus hendra y nipah.
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US9492559B2 (en) 2014-01-21 2016-11-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015123291A1 (fr) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Vaccin à base de pcsk9 et méthodes d'utilisation dudit vaccin
AU2015218909A1 (en) 2014-02-19 2016-08-04 Emergent Biosolutions Canada Inc. Marburg monoclonal antibodies
KR101966408B1 (ko) 2014-04-10 2019-04-05 오비아이 파머 인코퍼레이티드 항체，약학적 조성물 및 이의 용도
HRP20230416T1 (hr) 2015-01-15 2023-07-07 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka
US10478487B2 (en) * 2015-01-16 2019-11-19 Zoetis Services Llc Foot-and-mouth disease vaccine
EP3302536A1 (fr) 2015-06-03 2018-04-11 Affiris AG Vaccins d'il-23-p19
AU2016289497A1 (en) 2015-07-07 2017-12-07 Affiris Ag Vaccines for the treatment and prevention of IgE mediated diseases
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
KR20180050339A (ko) 2015-09-04 2018-05-14 오비아이 파머 인코퍼레이티드 글리칸 어레이 및 사용 방법
DK3307322T3 (da) 2015-09-04 2021-04-19 Primatope Therapeutics Inc Humaniserede anti-cd40-antistoffer og anvendelser deraf
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
JP2019513144A (ja) 2016-03-29 2019-05-23 オービーアイ ファーマ，インコーポレイテッド 抗体、医薬組成物及び方法
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
KR20230110820A (ko) 2016-04-22 2023-07-25 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
KR20190067765A (ko) 2016-07-27 2019-06-17 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
CA3044274A1 (fr) 2016-11-21 2018-05-24 Obi Pharma, Inc. Molecules biologiques conjuguees, compositions pharmaceutiques et procedes
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composições imunogênicas para uso em vacinas pneumococais
WO2019173438A1 (fr) 2018-03-06 2019-09-12 Stc. Unm Compositions et méthodes pour faire baisser les triglycérides sériques
TW202035444A (zh) 2018-06-27 2020-10-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020055503A1 (fr) 2018-09-14 2020-03-19 Massachusetts Institute Of Technology Adjuvant vaccinal à base de nanoparticules, et méthodes d'utilisation associées
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
WO2020154595A1 (fr) 2019-01-24 2020-07-30 Massachusetts Institute Of Technology Plateforme de nanostructure d'acide nucléique pour présentation d'antigène et formulations de vaccin formées grâce à son utilisation
CN109663126A (zh) * 2019-03-01 2019-04-23 龙阔（苏州）生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN112516325B (zh) * 2019-09-18 2023-12-08 洛阳赛威生物科技有限公司 一种稳定的口蹄疫疫苗组合物及其应用
WO2021084429A1 (fr) 2019-11-01 2021-05-06 Pfizer Inc. Compositions d'escherichia coli et méthodes associées
IL295632A (en) 2020-02-23 2022-10-01 Pfizer Escherichia coli preparations and their methods
CN113967252B (zh) * 2020-07-24 2024-03-26 洛阳赛威生物科技有限公司 一种禽用免疫增强剂、含有免疫增强剂的疫苗组合物及其应用
WO2022090893A2 (fr) 2020-10-27 2022-05-05 Pfizer Inc. Compositions d'escherichia coli et procédés associés
WO2022097010A1 (fr) 2020-11-04 2022-05-12 Pfizer Inc. Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (fr) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogènes imitant la pcsk9 guidés par des anticorps et ne présentant pas de chevauchement de séquence de 9 résidus avec des protéines humaines
WO2023114570A1 (fr) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions et méthodes pour obtenir des réponses durables des centres germinatifs à une sensibilisation active
WO2023154960A1 (fr) 2022-02-14 2023-08-17 University Of Georgia Research Foundation, Inc. Compositions de vaccins pan-pneumovirus et leurs méthodes d'utilisation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1924304C3 (de) * 1969-05-13 1980-07-17 Bayer Ag, 5090 Leverkusen Diäthylaminoäthyldextran (DEAE-D) als Adjuvans für Impfstoffe zur aktiven Immunisierung von Säugetieren
DE3411224A1 (de) 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
DK166762B1 (da) * 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
WO1988005308A1 (fr) * 1987-01-14 1988-07-28 Commonwealth Scientific And Industrial Research Or Hormone contraceptive
GB8707398D0 (en) * 1987-03-27 1987-04-29 Coopers Animal Health Biologically active molecules
US4892830A (en) * 1987-04-02 1990-01-09 Baylor College Of Medicine Environmentally controlled in vitro incubator
GB2228262B (en) 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
AU5186090A (en) 1989-02-23 1990-09-26 Colorado State University Research Foundation Gnrh analogs for destroying gonadotrophs
DE69027983T2 (de) * 1989-08-25 1997-03-20 Biotech Australia Pty Ltd Fusionsproteine bestehend aus TraTp und mindestens einem LHRH-Analog
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
GB8921470D0 (en) * 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
US5324512A (en) 1990-12-26 1994-06-28 The Population Council [Gln']-luteinizing hormone releasing hormone conjugate of tetanus vaccine and its uses
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
ZA934199B (en) 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO1997015316A1 (fr) 1995-10-27 1997-05-01 Merck & Co., Inc. Conjugues de gonadoliberine
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPO776897A0 (en) * 1997-07-09 1997-07-31 Csl Limited A method of achieving production gains in livestock and agents useful for same
US6013770A (en) 1997-07-21 2000-01-11 Washington State University Chimeric contraceptive vaccines
AUPP060097A0 (en) * 1997-11-28 1998-01-08 Commonwealth Scientific And Industrial Research Organisation Adjuvant system for enhanced response

Also Published As

Publication number Publication date
US20120251566A1 (en) 2012-10-04
CY1108693T1 (el) 2012-05-23
EP1140165B1 (fr) 2008-10-08
NZ512011A (en) 2002-12-20
JP2012072157A (ja) 2012-04-12
CA2359111A1 (fr) 2000-07-20
EP1946773A3 (fr) 2008-07-30
JP2002534480A (ja) 2002-10-15
EP1140165A4 (fr) 2005-01-05
AU2526300A (en) 2000-08-01
ZA200105543B (en) 2003-01-22
PT1140165E (pt) 2009-01-13
DE69939706D1 (de) 2008-11-20
WO2000041720A1 (fr) 2000-07-20
EP1140165A1 (fr) 2001-10-10
WO2000041720A8 (fr) 2000-11-09
CA2660344A1 (fr) 2000-07-20
US9579379B1 (en) 2017-02-28
EP1946773A2 (fr) 2008-07-23
ATE410183T1 (de) 2008-10-15
JP4949555B2 (ja) 2012-06-13
ES2317708T3 (es) 2009-04-16
AU758133B2 (en) 2003-03-13
TW533079B (en) 2003-05-21
AUPP807399A0 (en) 1999-02-04
CA2359111C (fr) 2014-02-18
US9149520B2 (en) 2015-10-06

Similar Documents

Publication Publication Date Title
DK1140165T3 (da) Fordbedrede adjuvanssammensætninger baseret på saponin og dermed tilhörende metoder
GB2303854B (en) Helicobacter proteins and vaccines
AU4324996A (en) Novel cyclodextrin-derivatives and methods for the preparation thereof
HK82392A (en) Polyoxypropylene-polyoxyethylene block polymer based adjuvants and vaccines using them
HU9904549A (en) Vaccines
NO970993D0 (no) Mutant enterotoksin som er effektiv som en ikke-toksisk oral adjuvant
EP1955709A3 (fr) Compositions d'adjuvant d'amélioration des réponses immunitaires aux vaccins à base de polynucléotide
CA2217178A1 (fr) Vaccins contenant une saponine ainsi qu'un sterol
AU4195897A (en) Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof
ES2179105T3 (es) Adyuvantes proteinicos.
EP1326633A4 (fr) Composition comprenant des microparticules immunogenes
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
NZ314585A (en) Method of treating H. Pylori associated gastroduodenal disease
PT792165E (pt) Composicoes imunogenicas
CA2352563A1 (fr) Methode de preparation de vaccins inactives associes a une emulsion eau dans huile adjuvante
WO2000006198A3 (fr) Adjuvant comprenant un tensioactif pulmonaire
AR010568A1 (es) Polipeptido, composicion de vacuna, uso del polipeptido en la fabricacion de una composicion, y metodo para producir en un mamifero una respuestainmuno-protectora contra la infeccion de helicobacter pylori
DK0485463T3 (da) Svækket hundeparvovirus (CPV), vaccine omfattende CPV og fremgangsmåde til forebyggelse af CPV-infektion i hunde
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
NL300073I1 (nl) Vaccin.
WO1999002182A3 (fr) Vaccins non aqueux
WO2001043768A3 (fr) Nouvelle composition de vaccin
MX9700215A (es) Proteinas y vacunas de helicobacter.
DK0563288T3 (da) Immunopotentiering af vacciner, navnlig svinepleuropneumoniavacciner
SE9600646D0 (sv) Vaccin